Nominating Committee Appointed for Upcoming Meeting
STOCKHOLM — The recent appointment of the nominating committee for SciBase Holding sets an important stage for the company's upcoming Annual General Meeting in 2026. This committee plays a critical role in shaping the direction and governance of the organization.
Members of the Nominating Committee
The nominating committee consists of the following appointed members:
- Anders Bladh from Ribbskottet AB,
- Derek Maetzold from Castle Biosciences Inc,
- Maria Anderkvist from Coeli Wealth Management,
- Jesper Høiland, who serves as the Chairman of the Board.
This selection reflects the commitment to ensuring a diverse and capable set of individuals to guide the strategic decisions facing SciBase. Their first task will be to assess the needs of the company and identify candidates for the board ahead of the seminal meeting.
Guidelines for Shareholder Involvement
According to established protocols outlined at the last Annual General Meeting, shareholders are encouraged to participate actively in the process. If shareholders wish to propose any agenda items for consideration by the nominating committee, they should forward their suggestions in writing to the Chairman of the Board. This can be done through postal services, ensuring that the correspondence reaches the appropriate address in good time.
Furthermore, any items meant for discussion at the Annual General Meeting must be submitted to the Board at least seven weeks prior to the event. This timeline is crucial to ensure that the Board can adequately prepare for the meeting and that all matters are included in the official notice sent to the shareholders.
About SciBase Holding
SciBase Holding AB (publ) is recognized as a frontrunner in medical technology, particularly in dermatology. The company is well-known for its innovative approach towards early detection and prevention of skin-related conditions. Its flagship product, Nevisense, utilizes advanced electrical impedance spectroscopy (EIS) technology paired with artificial intelligence to enhance diagnostic accuracy.
SciBase is committed to advancing patient care by offering tools that allow healthcare professionals to intervene sooner in skin health, potentially saving lives and reducing healthcare costs overall.
Founded on two decades of research stemming from Karolinska Institute, SciBase’s dedication to innovation in dermatology ensures that it remains at the forefront of developments in skin disease management.
Furthermore, the company has been publicly listed on the Nasdaq First North Growth Market since June 2015, which supports its drive for increased investment in research and development.
Contact Information
For further details regarding the newly formed nominating committee or any other inquiries, stakeholders can reach out
- Jesper Høiland, Chairman of the Board, phone: +45 612 207 30
- Michael Colérus, CFO, phone: +46 70 341 34 72
Investors and interested parties can also connect with the certified advisor, DNB Carnegie Investment Bank, via phone at +46 8 588 68 570 for any related questions.
Frequently Asked Questions
What is the purpose of the nominating committee?
The nominating committee is responsible for proposing candidates for the Board of Directors and ensuring the effective governance of the company.
When is the Annual General Meeting scheduled to occur?
The Annual General Meeting for SciBase Holding is set for May 19, 2026.
How can shareholders suggest topics for the agenda?
Shareholders can submit their suggestions in writing to the Chairman of the Board at the company's designated postal address.
Who are the key members of the new nominating committee?
The committee includes Anders Bladh, Derek Maetzold, Maria Anderkvist, and Jesper Høiland as the Chairman.
What products does SciBase specialize in?
SciBase specializes in medical technology for dermatology, particularly focusing on early detection of skin conditions through its product Nevisense.
